CheckMate 8HW: Nivolumab + Ipilimumab Shows Durable PFS Benefit in MSI-H/dMMR CRC

Michael Foote, MD, Memorial Sloan Kettering Cancer Center, discusses the final results from the CheckMate 8HW trial, including the three study arms: nivolumab plus ipilimumab, nivolumab alone, and standard chemotherapy.

The FDA recently approved nivolumab plus ipilimumab for patients with mismatch repair-deficient stage IV colorectal cancer based on these study results.

Advertisement

Latest News

Advertisement
Advertisement
Editorial Advisory Board

Roundtable Discussions

Conference Coverage

Knowledge Hubs

Bile Duct